At the time of writing, Aardvark Therapeutics Inc [AARD] stock is trading at $15.37, up 0.13%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AARD shares have gain 7.71% over the last week, with a monthly amount glided 10.42%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aardvark Therapeutics Inc [NASDAQ: AARD] stock has seen the most recent analyst activity on December 23, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $35. On December 03, 2025, Raymond James initiated with a Strong Buy rating and assigned a price target of $47 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $26 on November 07, 2025. Stifel initiated its recommendation with a Buy and recommended $24 as its price target on September 29, 2025. H.C. Wainwright started tracking with a Buy rating for this stock on June 30, 2025, and assigned it a price target of $40. In a note dated March 10, 2025, RBC Capital Mkts initiated an Outperform rating and provided a target price of $21 on this stock.
For the past year, the stock price of Aardvark Therapeutics Inc fluctuated between $4.88 and $19.58. Currently, Wall Street analysts expect the stock to reach $31 within the next 12 months. Aardvark Therapeutics Inc [NASDAQ: AARD] shares were valued at $15.37 at the most recent close of the market. An investor can expect a potential return of 101.69% based on the average AARD price forecast.
Analyzing the AARD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.55 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Aardvark Therapeutics Inc [NASDAQ:AARD] has a current ratio of 12.03. In addition, the Quick Ratio stands at 12.03 and the Cash Ratio stands at 3.66.
Transactions by insiders
Recent insider trading involved Sun Nelson, Chief Financial Officer, that happened on Dec 11 ’25 when 3000.0 shares were purchased. Chief Executive Officer, Lee Tien-Li completed a deal on Dec 11 ’25 to buy 7000.0 shares. Meanwhile, Chief Executive Officer Lee Tien-Li bought 10000.0 shares on Sep 15 ’25.
